About IPI
The Institute for Protein Innovation (IPI) is an independent nonprofit research institute dedicated to advancing protein science and accelerating biomedical discovery by developing and distributing high quality, well-validated recombinant protein tools. Founded in 2017 by Timothy A. Springer, Ph.D. and Andrew C. Kruse, Ph.D., IPI is headquartered on the Harvard Medical School campus in the Longwood Medical and Academic Area in Boston.
IPI provides open access synthetic recombinant antibodies and other protein reagents, with a focus on human extracellular and secreted proteins, to support reproducible and reliable research. The institute operates a high throughput antibody discovery platform using yeast display technology and automated laboratory systems to produce and validate antibodies at scale.
Through a partnership with Addgene, IPI distributes its reagents globally under an open science model, providing researchers with antibodies, associated plasmids, sequences, and validation data where available. The institute also conducts internal research programs with a focus on neurobiology and offers educational initiatives to train the next generation of protein scientists.
IPI’s publicly available collections include integrin antibodies, epitope tag antibodies, glypican antibodies, and neurobiology relevant antibodies, with ongoing development and validation. Its funding combines philanthropic support, revenue from reagent distribution, and sponsored research, enabling IPI to advance its mission without a profit motive.